Literature DB >> 30365048

Deletion of FOXL2 by CRISPR promotes cell cycle G0/G1 restriction in KGN cells.

Bin Tang1, Yujie Zhang2, Wei Zhang2, Yuqing Zhu1, Shaopeng Yuan3.   

Abstract

Forkhead box L2 (FOXL2), a member of the forkhead family of transcription factors, is important in eyelid and ovary differentiation. Although the function of FOXL2 in organogenesis has been investigated, the detailed mechanisms by which FOXL2 mediates cellular process remain to be fully elucidated. Few FOXL2‑knockout cell lines have been reported, which has limited molecular mechanism investigations. CRISPR is a novel gene editing technique that has been widely used in human genetic diseases. In the present study, FOXL2 was disrupted using clustered regularly interspaced short palindromic repeats (CRISPR), and screening of a stable knockout cell line was performed in human ovarian granulosa KGN cells. Three sites (F404, F425 and F446) around the ATG start codon on the FOXL2 DNA sequence were constructed in a guide RNA lentivirus. Targeting F425 was most efficient, and western blot analysis and DNA sequencing of the resulting cells suggested that both FOXL2 alleles were fully disrupted. In addition, flow cytometry results indicated that the knockout of FOXL2 restricted cell cycle progression at the G0/G1 phase. In addition, the expression levels of cell cycle mediators cyclin D1 and cyclin‑dependent kinase 4 were reduced. These results confirmed that FOXL2 disruption in KGN cells is associated with the cell cycle attenuation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30365048     DOI: 10.3892/ijmm.2018.3956

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  1 in total

1.  Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors.

Authors:  Stine E Weis-Banke; Mads Lerdrup; Daniela Kleine-Kohlbrecher; Faizaan Mohammad; Simone Sidoli; Ole N Jensen; Toshihiko Yanase; Tomoko Nakamura; Akira Iwase; Anthe Stylianou; Nadeem R Abu-Rustum; Carol Aghajanian; Robert Soslow; Arnaud Da Cruz Paula; Richard P Koche; Britta Weigelt; Jesper Christensen; Kristian Helin; Paul A C Cloos
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.